Warning
Cipla USA Recalls Lanreotide Injection
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0290-2026Drug / Pharmaceutical
Cipla USA Recalls Lanreotide Injection
Cipla USA, Inc. · Class II — Moderate Risk
Product Description
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
Reason for Recall
Presence of Particulate Matter.
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide in the USA
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Cipla USA, Inc. initiated the recall on January 2, 2026 affecting 15,221 syringes. Presence of Particulate Matter. The product was distributed nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Cipla USA, Inc. for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination and Cipla USA recalls.